Programmed death-1 (PD-1) belongs to the CD28 family of co-stimulatory and co-inhibitory molecules and regulates adaptive immunity. This molecule induces the development of regulatory T cells, T cell tolerance, or apoptosis. We examined the role of PD-1 pathway in Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease (TMEV-IDD) mice. Up-regulation of PD-1 and PD-1 ligand-1 (PD-L1) mRNA expression in bone marrow-derived dendritic cells were induced by TMEV infection in vitro. Furthermore, PD-1 and PD-L1 mRNA expression was increased in the spinal cords of the TMEV-infected mice in vivo. Treatment with a blocking monoclonal antibody (mAb) against PD-1, especially during the effector phase, resulted in significant deterioration of the TMEV-IDD both clinically and histologically. Flow cytometric analysis revealed a dramatically increase of CD4 + T cells producing Th1 cytokines such as IFN-γ and TNF-α in the spinal cord of anti-PD-1 mAbtreated mice. These results indicate that the PD-1 pathway plays a pivotal regulatory role in the development of TMEV-IDD.
Introduction
Multiple sclerosis (MS) is an immune-mediated chronic inflammatory demyelinating disease of the central nervous system (CNS) in humans (Wekerle, 1991) . Although the etiology of MS is not clarified yet, epidemiological studies and investigations with experimental animal models have supported a potential role for viruses as the environmental trigger in disease induction (Allen and Brankin, 1993) . Thus, a similar demyelinating disease induced by a virus could be one of the most attractive animal models in the study of the pathogenesis of MS. Theiler's murine encephalomyelitis viruses (TMEV), members of the genus Cardiovirus in the family of Picornaviridae, are natural enteric pathogens that cause CNS disease in mice (Pevear et al., 1987) . Intracerebral (i.c.) injection of TMEV into susceptible strains of mice results in a chronic, progressive demyelinating disease characterized histologically by perivascular inflammatory cell infiltrates and primary demyelination of the CNS (Lipton and Dal Canto, 1976) . The clinical signs of TMEVinduced demyelinating disease (TMEV-IDD) include a spastic waddling gait, extensor spasm, and incontinence (Lehrich et al., 1976) . TMEV-IDD is considered an infectious mouse model for MS because the disease displays histopathologic, genetic, and clinical similarities to human MS (Dal Canto and Lipton, 1975; Nathanson and Miller, 1978; Kurtzke and Hyllested, 1986; Kappel et al., 1991) . The demyelination is linked to persistent TMEV infection in the CNS (Lipton et al., 1991) , and histological findings are characterized by perivascular inflammatory cell infiltrates and primary demyelination in CNS (Lehrich, Arnason, 1976; Lipton et al., 1984) . TMEV persists in the white matter of the spinal cord, mainly in microglia/macrophages, but also in astrocytes and oligodendrocytes throughout the life of a mouse (Lipton et al., 1984; Lipton et al., 1995) . Persistent CNS virus infection in susceptible mouse strains triggers clonal expansion and differentiation of TMEV-specific T cells that are poorly controlled by normal immunoregulatory mechanism. Activated Th1 cells release proinflammatory cytokines in the CNS, resulting in the subsequent recruitment and activation of mononuclear phagocytes that initiate myelin destruction via both direct and bystander mechanisms (Miller et al., 1997a; Kim et al., 1998) . Furthermore, approximately 4 weeks after onset of clinical disease, i.e., 8 weeks post infection, T-cell responses to myelin epitopes arise in an ordered temporal progression (Miller et al., 1997b) consistent with a role for both virusand myelin-specific responses in the chronic phase of the disease.
The immune system has the difficult challenge of discerning and defending against a diversity of microbial pathogens, while simultaneously avoiding self-reactivity. While central tolerance mechanisms result in deletion of the majority of self-reactive T lymphocytes, some T cells specific for self-antigens escape into the periphery (van Noort et al., 1993; Lohmann et al., 1996) . To further control the development of autoimmunity, multiple mechanisms of peripheral tolerance have Journal of Neuroimmunology 274 (2014) 78-85 
